According to these findings, we concluded that GATA3-AS1 detected using RNA-ISH can be used as a biomarker for predicting pathologic complete response in patients with locally advanced luminal B breast carcinoma, and that RNA-ISH is an adequate technique for determining its expression. The gene discussed is GATA3; the disease is breast carcinoma.